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Combined Application of Bacterial 
Predation and Violacein to 
Kill Polymicrobial Pathogenic 
Communities
Hansol Im, Seong Yeol Choi, Sangmo Son & Robert J. Mitchell
Violacein is a bisindole antibiotic that is effective against Gram-positive bacteria while the bacterial 
predator, Bdellovibrio bacteriovorus HD100, predates on Gram-negative strains. In this study, we 
evaluated the use of both together against multidrug resistant pathogens. The two antibacterial 
agents did not antagonize the activity of the other. For example, treatment of Staphylococcus aureus 
with violacein reduced its viability by more than 2,000-fold with or without B. bacteriovorus addition. 
Likewise, predation of Acinetobacter baumannii reduced the viability of this pathogen by more than 
13,000-fold, regardless if violacein was present or not. When used individually against mixed bacterial 
cultures containing both Gram-positive and Gram-negative strains, violacein and B. bacteriovorus 
HD100 were effective against only their respective strains. The combined application of both violacein 
and B. bacteriovorus HD100, however, reduced the total pathogen numbers by as much as 84,500-fold. 
Their combined effectiveness was also demonstrated using a 4-species culture containing S. aureus, 
A. baumannii, Bacillus cereus and Klebsiella pneumoniae. When used alone, violacein and bacterial 
predation reduced the total population by only 19% and 68%, respectively. In conjunction with each 
other, the pathogen viability was reduced by 2,965-fold (99.98%), illustrating the prospective use of 
these two antimicrobials together against mixed species populations.
Within nature, bacteria are found primarily within polymicrobial communities. This is also true of infections, 
which may include both pathogens and commensal microbes1,2. One benefit that bacteria within these communi-
ties gain is an increased resistance to antibiotics3,4. Two reasons for this include the presence of resistant strains5,6, 
which can degrade the antibiotic, or because the other strains act as a “sink” for the antibiotic, diluting its impact 
on the susceptible populations7. To overcome this, researchers have often resorted to using a combination of 
antibiotics8–10.
Antibiotic resistance on a single species level can be either intrinsic or acquired. Intrinsic resistance is a char-
acteristic that is coded for in the genome of the strain, independent of antibiotic pressure and not a consequence 
of horizontal gene transfer. An example of intrinsic resistance includes the outer membrane in Gram-negative 
bacteria, which modulates the cell permeability and limits the entry of hydrophobic antibiotics11. Lacking an 
outer membrane, Gram-positive strains are generally less protected and antibiotics may enter these bacteria more 
easily12. The result is that Gram-negative bacteria are less susceptible to many antibiotics that are effective against 
Gram-positive pathogens.
A case in point is the bisindole antibiotic violacein, which is produced by a number of bacterial species13, 
including strains of Chromobacterium14,15, Janthinobacterium16, Collimonas17 and Duganella18. As an antibiotic, 
violacein is primarily active against Gram-positive strains15,18–20, particularly Staphylococcus aureus20–22. It was 
also active against multidrug-resistant S. aureus23, including one strain that is resistant to seven different antibiot-
ics, i.e., rifampin, ciprofloxacin, clindamycin, oxacillin, erythromycin, gentamycin and tobramycin18. Violacein, 
however, is generally ineffective against Gram-negative strains.
In addition to conventional chemical-based antibiotics, several groups are also considering the use of 
predatory bacterial strains as living antibacterial agents24–26. These strains are commonly referred to as 
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Bdellovibrio-and-like-organisms (BALOs). The best characterized BALO is probably Bdellovibrio bacteriovorus 
HD100, an obligate predator of bacteria that is known to attack more than 100 different human pathogens27–30, 
including multidrug resistant strains of Acinetobacter baumannii and Klebsiella pneumoniae28. When it attacks its 
prey, B. bacteriovorus enters the periplasmic space and consumes its prey from within, where this predator grows, 
septates and eventually lyses the outer membrane of the prey to facilitate its release. In contrast with violacein, the 
activity of BALOs is limited to only Gram-negative bacterial strains29–32.
Given the inherent limitations associated with both violacein and B. bacteriovorus, we proposed they might be 
used in conjunction with one another to expand their individual spectrums of killing. To test this, B. bacteriovorus 
and violacein were partnered together and their activities evaluated using individual bacterial and polymicrobial 
populations, with an emphasis on those that included both Gram-negative and Gram-positive pathogens.
Materials and Methods
Bacterial strains and culturing techniques. The bacterial strains used in this study are listed in Table 1. Each of 
these strains was grown in Lysogeny Broth (LB) broth (Difco BD, USA) overnight at 30 °C and 250 rpm. To examine 
the impact of the treatment by predatory bacteria or violacein, the bacterial culture were prepared by centrifuging 
with 2,200 × g for 10 min (5430 R, Eppendorf, USA) and resuspended in HEPES buffer (pH 7.2) to an optical density 
(OD) of 1.0 at 600 nm wavelength. B. bacteriovorus HD100 was cultured as described previously33,34.
Violacein extraction from Pseudoduganella violaceinigra sp. NI28 cultures. Violacein was 
extracted from cultures of Pseudoduganella violaceinigra sp. NI28 as described previously18. After dissolving the 
violacein in ethanol, the solution was filtered using a 0.22um syringe filter (Millipore, USA) and the ethanol was 
evaporated (EYELA N1110, Tokyo Rikakikai Co., Japan). The violacein was crystallized using an acetone wash 
designed to remove any contaminating salts35 and dissolved in DMSO (99.7% HPLC Grade, Sigma Aldrich, USA) 
to a final concentration of 2 g/L.
Antimicrobial treatment. Overnight cultures of the bacterial strains were pelleted (2,200 × g, 10 min) and 
resuspended in HEPES buffer to an OD of 1.0 (600 nm). Each individual culture was then challenged with pred-
atory bacteria or violacein. For the predatory tests, overnight cultures of B. bacteriovorus HD100 were filtered 
and added to the mixed bacterial suspension to achieve a predator-to-prey ratio (PPR) of 0.02~0.05. Similarly, 
for the violacein tests, violacein was added to the mixed bacterial suspension to a final concentration of 20 mg/
ml. The cell viability (colony forming units (CFU)) was measured after each treatment. For the dual treatment 
experiments using predatory bacteria and violacein together, the same conditions were applied.
Likewise, for the mixed species tests, the cultures were prepared by adding equal volumes of each bacterial 
resuspension prior to addition of violacein and/or B. bacteriovorus HD100. Differences in the colony morpholo-
gies were used to differentiate between the two strains when we determined the viabilities of these cultures. For 
the four strain experiments, individual strains could not be differentiated between based upon the colony mor-
phology and, so, the total viability was determined by plating serial dilutions of the cultures on LB agar plates and 
enumerating the colonies after 24 h at 37 °C.
Microscopic imaging. Microscopic images were obtained using a Zeiss LSM 780 NLO microscope. To visu-
alize the bacterial strains, dyes were used. Prior to treatment with either violacein or B. bacteriovorus HD100, each 
of the bacterial cultures were mixed with 6 µM Syto-9 (Invitrogen, USA). This is a live stain and all viable bacterial 
cells were fluorescently green afterwards. After washing the cells with HEPES to remove any extra dye, they were 
exposed to either the predatory cells (PPR of 0.1) or 20 mg/ml of violacein in HEPES. After one hour, propidium 
iodide (Invitrogen, USA) was added to the bacterial cultures to a final concentration of 30 µM. This dye is a dead 
stain and labels any non-viable bacterial cells red. After 30 minutes at room temperature, the cells were pelleted 
(16,000 × g, 5 min), washed and resuspended in HEPES before being imaged.
Antibiotic resistance determination. To determine the antibiotic resistant nature of the bacterial strains, 
we used the same protocol as described previously18. Strain resistance was determined using the latest breakpoint 
tables available at the European Committee on Antimicrobial Susceptibility Testing (EUCAST) website (http://
www.eucast.org/clinical_breakpoints/).
Bacterial Strains Characteristics Ref
S. aureus ATCC 25923
B. cereus ATCC 14579
S. epidermidis ATCC  14990
A. baumannii Clinical isolate PNUHa
E. coli MG1655 Common lab strain; multidrug resistant
K. pneumoniae Clinical isolate; multidrug resistant PNUHa
S. aureus CCARM 3090 Clinical isolate; multidrug resistant (18)b
Table 1. Bacterial strains used in this study. aClinical strains isolated at the Pusan National University Hospital, 
Yangsan Campus. bObtained from the Culture Collection of Antimicrobial Resistant Microbes (http://knrrb.
knrrc.or.kr/index.jsp?rrb=ccarm).
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Spot viability assay. To compare the activity of conventional antibiotics and the dual treatment protocol used 
in this study, we tested representative bacteriostatic and bactericidal antibiotics, i.e., chloramphenicol and gentamy-
cin, respectively. For the assays, a concentrated dosage that was 10-fold higher than the typical dose used in labs was 
employed. As such, the bacterial community was exposed to either 350 mg/l chloramphenicol, 500 mg/l gentamicin 
or both. After treatment, the cells viabilities were evaluated using a spot viability plate. For this, the exposed cultures 
were serially diluted into LB media and 10 µl was spotted on LB agar within a square petridish (SPL, Korea) and 
incubated for 24 hour at 37 °C. The extent of growth was used as an indication of viability.
Statistical analysis. In this research, all assays were accomplished at least three replicates and the standard 
deviations among the samples are indicated with error bars on the graphs. Statistical analysis was done using 
Student’s t-test to compare two sets of results and the statistical significance was marked on the graphs using the 
marks *, **, *** for p-values of less than 0.05, 0.01, and 0.001 respectively. For comparing three or more data sets, 
analysis of variance (ANOVA) tests were performed followed by the Tukey post-hoc test. Statistically, significantly 
different groups using a p-value < 0.05 are shown on the graphs using letters (a, b, c and d).
Results
Activity Spectrum of Violacein and Bacterial Predation. Violacein is quite active against S. aureus, 
killing more than 99% of the culture when added at a concentration of 20 mg/L or greater18,21,23. Using this con-
centration, we tested the activity of violacein against six different strains (Tables 1 and 2), including three Gram-
positive and three Gram-negative species. As shown in Fig. 1a, only the Gram-positive cultures were sensitive to 
violacein, with each showing significant viability losses after 24 hours. In contrast, none of the Gram-negative cul-
tures were negatively impacted by violacein (Fig. 1a). The A. baumannii and K. pneumoniae strains used through-
out this study were multidrug resistant clinical isolates (Table 2).
The results with B. bacteriovorus HD100 stood in stark contrast as only the Gram-negative strains experienced 
a loss in their viabilities (Fig. 1b). These results clearly illustrate the different activity spectrums for both antimi-
crobials and highlight the limitations of each. This dichotomy is further demonstrated in Fig. 1c where S. aureus 
or E. coli were imaged after being exposed to either. In agreement with Fig. 1a and b, violacein only killed S. aureus 
while B. bacteriovorus HD100 only killed E. coli.
Violacein and B. bacteriovorus Do Not Adversely Impact Each Other’s Activity. The above data 
shows violacein was not active against the three Gram-negative strains. Given B. bacteriovorus HD100 is also 
Gram-negative, we speculated that violacein would also not be harmful towards this predator or its activity. 
Figure 2a shows that this was the case when A. baumannii was used as the prey strain. In both cases, the A. bau-
mannii populations were similarly reduced by more than 4-log due to the activity of B. bacteriovorus HD100. 
Similarly, the activity of violacein was not thwarted by the presence of B. bacteriovorus HD100, as illustrated in 
Fig. 2b. This figure shows reduction of the S. aureus populations was comparable whether or not the predator was 
added.
The Activities of Violacein and B. bacteriovorus are Compatible with Each Other. We next 
tested the possibility of using both treatments together against cultures containing both a Gram-positive and a 
Gram-negative strain. For these tests, we selected S. aureus (average initial population: 4.2 × 108 CFU/ml) and 
either A. baumannii or K. pneumoniae (average initial population: 7.9 × 108 CFU/ml).
As shown in Fig. 3a, both antimicrobials were active against their respective pathogen: treatment with viola-
cein alone killed only S. aureus while the use of B. bacteriovorus HD100 by itself only reduced the A. baumannii 
population. As a result, the total pathogen number did not decrease very much, i.e., only 51% with violacein 
and 69% with B. bacteriovorus HD100. When violacein and B. bacteriovorus HD100 were used together, how-
ever, both pathogens were significantly killed and the total pathogen numbers were reduced by 99.8% (620-fold). 
Similar results were obtained when S. aureus and K. pneumoniae were cultured together (Fig. 3b) as individual 
treatments with violacein and B. bacteriovorus HD100 led to a 41% and 81% loss in total pathogens, respectively, 
while a dual treatment caused a 99.999% (84,500-fold) reduction in the pathogen viability.
Dual treatment tests were also performed using either A. baumannii or K. pneumoniae alongside a different 
Gram-positive bacteria, i.e., S. epidermidis (Fig. 4). In both cultures, the viability of each pathogen was reduced 
by more than 99.3%.
Application of the Dual Treatment to a Complex Microbial Community. Subsequently, we tested if 
a dual treatment is also effective against a complex microbial consortium harboring four different human patho-
gens, i.e., S. aureus, A. baumannii, B. cereus and K. pneumoniae (Fig. 5). The population of each pathogenic strain 
AMP CIP GEN TET CM RIF ERY CC
A. baumannii 0(R) 0(R) 0(R) 18–22(S) 12–15(I) 15–17(S) 15–17(S) ND
K. pneumoniae 9–10(R) 29–30(S) 20–21(S) 24–25(S) 23–25(S) 6–8(R) 6–8(R) ND
S. aureus CCARM 3090 9–10(R) 0(R) 23–25(S) 9–10(R) 22–25(S) 30–35(S) 0(R) 0(R)
Table 2. Antibiotic resistance of the clinical isolates used in this study. The highlighted values are indicative of 
resistance. AMP: ampicillin, CIP: Ciprofloxacin, GEN: Gentamycin, TET: Tetracycline, CM: Chloramphenicol, 
RIF: Rifampicin, ERY: Erythromycin, CC: Clindamycin. Classifications: (R) – Resistant; (I) – Intermediate; (S) – 
Susceptible; ND – Not determined.
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is listed in Table 3, with a total initial population of 5.9 × 108 CFU/ml. After treatment with either B. bacteriovorus 
HD100 or violacein alone, the Gram-negative and Gram-positive strain viabilities decreased, respectively, but 
we could not reliably measure the impact due to the overwhelming presence of the surviving strains. The use of 
Figure 1. Spectrum of activity for violacein and B. bacteriovorus HD100. (a and b) The activity of each 
antimicrobial was evaluated using three Gram-positive and three Gram-negative bacterial strains. The 
pathogens were treated with either (a) 20 mg/l violacein or (b) 1 × 107 PFU/ml of B. bacteriovorus HD100. 
The viabilities of the pathogens were determined initially and after 24 hrs (n = 4). (c) Impact of violacein 
and B. bacteriovorus HD100 on S. aureus and E. coli. The bacteria were treated with either 20 mg/l 
violacein or approximately 1 × 107 PFU/ml of B. bacteriovorus HD100 for 1 hr. Using the Live/Dead 
BacLight kit, the viable and non-viable bacteria were fluorescently labeled and imaged using confocal 
microscopy. Scale bar – 10 µm.
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violacein alone resulted in a 19% reduction of the total number of pathogens while B. bacteriovorus HD100 led to 
a 68% loss (3.1-fold). As shown in Fig. 5, when both antimicrobials were used, the number pathogens was reduced 
by 99.96% (2,970-fold).
Dual Treatment Impacts on Multidrug Resistant Bacterial Populations. As a final test using both 
predatory bacteria and violacein together, a test culture containing multidrug resistant S. aureus (Table 2) was 
prepared. The other strain was the same A. baumannii as above, which is also multidrug resistant. Both of these 
strains are resistant to numerous antibiotics, as listed in Table 2, and the initial population of each pathogen 
within the cultures was 5.2 × 108 and 3.2 × 108 CFU/ml, respectively. For comparison, we also treated the mixed 
pathogen culture with a concentrated blend of gentamicin with chloramphenicol (Fig. 6). The image show the 
use of B. bacteriovorus HD100 and violacein was much more effective at killing the pathogens than the use of 
gentamicin and chloramphenicol, even though the concentrations of the two antibiotics were much higher than 
what is typically used.
Discussion
Due to the universal spread of antibiotic resistance, it is projected that the number of human mortalities each 
year resulting from antimicrobial resistant pathogens will surpass that caused by cancer by 205036. Two alterna-
tive antimicrobials currently being studied by various groups are violacein and predatory bacteria18,23,25,28,37,38. In 
addition to their antibiotic activities, both also show promising toxicology results, a key characteristic for broad 
spectrum antibiotics8,39; in tests with mice, violacein was non-toxic at concentrations as high as 1 mg/kg40 while B. 
bacteriovorus was not toxic towards several different animal hosts41–43 or in human cell cultures44–46.
Treatment of S. aureus with violacein not only led to a significant loss of viability but also caused a substantial 
degree of aggregation. Similar results were seen in other studies where S. aureus was exposed to either violacein22 
or galangin47. In the former study, violacein was shown to disrupt the membrane integrity of S. aureus, which led 
Figure 2. Violacein and B. bacteriovorus HD100 do not hinder the activity of the other. (a) Predation of A. 
baumannii with or without addition of 20 mg/l violacein. A. baumannii was predated on by B. bacteriovorus 
HD100 as effectively when violacein was present as when it was omitted. The viabilities were measured after 
24 h, as in Fig. 1. a and b = p < 0.05 (n = 3). (b) The activity of violacein against S. aureus with or without 
addition of B. bacteriovorus. The presence of the predatory bacterium did not negatively impact the activity of 
violacein against this pathogen. The viabilities were measured after 24 h, as in Fig. 1. a and b = p < 0.05 (n = 3).
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to a rupturing of the cell membrane and leakage of the cellular components. It was hypothesized by Cushnie et al. 
(2007) that galangin similarly damages the membrane and exposes the hydrophobic regions located within the 
phospholipid bilayer, which then interact and cause aggregation47. The same process likely occurs with violacein, 
which would account for the cell aggregates seen here. The activity of violacein also helps to explain the inherent 
resistance of Gram-negative bacterial strains since the outer membrane would act like a sponge and absorb viol-
acein, protecting the inner membrane. With B. bacteriovorus, however, only E. coli was killed while the S. aureus 
cells remained viable (Fig. 1c). This is a clear demonstration that S. aureus is not a prey for B. bacteriovorus and 
reaffirms the long held knowledge that BALOs only predate and consume Gram-negative strains29–32, despite 
claims in one study that S. aureus is also attacked48. Although the mode of activity for violacein has recently been 
resolved, much still remains unanswered about how predatory bacteria recognize, enter and kill their prey and the 
processes involved in each of these steps.
The results above illustrate inherent limitations for both violacein and B. bacteriovorus HD100; violacein is 
largely effective against Gram-positive bacteria while B. bacteriovorus HD100 attacks only Gram-negative strains. 
Given the different activity spectrums for these two antimicrobials, we proposed they might be complementary 
and used alongside each other against polymicrobial populations. However, it was not known if predatory bac-
teria and violacein negatively impact the activity of the other. Here we show that this was not the case – violacein 
was just as effective against S. aureus regardless of whether B. bacteriovorus was present while predation of A. 
baumannii proceeded just as successfully in the presence or absence of violacein. This suggested that they can be 
used together and hinted at their potential use to eradicate polymicrobial populations.
Polymicrobial infections are a serious problem since complex bacterial communities can benefit from the 
properties of each of the members. An example of this is the protection afforded to a susceptible population by 
a resistant member of the community, such as through enzymatic inactivation of the antibiotic5,6. Another pos-
sibility is the “inoculum effect”, whereby the antibiotic activity is diluted out by the presence of other bacteria, 
which act as “sinks” for the antibiotic and limit its effectiveness against susceptible microbe populations7. We were 
concerned that this may be a problem for violacein. Violacein is a hydrophobic compound and attacks cellular 
membranes, implying the presence of naturally-resistant Gram-negative bacterial cells may act as a “sink” for 
this antibiotic and dilute its impact on S. aureus or other Gram-positive pathogens. The results, however, suggest 
that this is not a problem as violacein at the concentration used was as effective at killing S. aureus regardless if A. 
baumannii or K. pneumoniae were present.
Likewise, although they are not attacked by B. bacteriovorus, Gram-positive strains may act as decoys and slow 
the predation of susceptible Gram-negative bacterial strains49. As B. bacteriovorus does not display a clear chemo-
taxis towards prey cells50, it is generally thought that interactions between B. bacteriovorus HD100 and its prey are 
random events that occur as the predator swims within the media. By extrapolation, this means B. bacteriovorus 
Figure 3. Treatment of two-strain cultures containing S. aureus with violacein and B. bacteriovorus HD100. 
(a) Impact of 20 mg/l violacein alone, 1 × 107 PFU/ml B. bacteriovorus HD100 alone or both together against 
a mixed culture containing S. aureus and A. baumannii. The viabilities were measured after 24 hr. Each of the 
antimicrobials was effective against their respective pathogen when used alone, but together led to a significant 
loss in the total pathogen numbers. a, b and c = p < 0.05 (n = 3). (b) Impact of 20 mg/l violacein alone, 
1 × 107 PFU/ml B. bacteriovorus HD100 alone or both together against a mixed culture containing S. aureus and 
K. pneumoniae. The viabilities were measured after 24 hr. Each of the antimicrobials was effective against their 
respective pathogen when used alone, but together led to a significant loss in the total pathogen numbers. a, b, c 
and d = p < 0.05 (n = 3).
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will also come in contact and interact with non-prey bacterial cells. Such interactions have been observed with 
both Neisseria gonorrhoeae51 and Bacillus subtilis49, although neither is predated upon. Stemming from this rea-
soning, Wilkinson (2001) developed the first mathematical model to describe the impact decoys may have on 
B. bacteriovorus predation rates and efficacies using a double-Monod framework based upon a continuous flow 
system52. Hobley et al. (2006) followed this with experimental data using B. subtilis as a decoy in predation cul-
tures with E. coli S17-1 as the prey, and developed their own model based upon the Lotka-Volterra equations49. 
They found predation rates were slower during the first seven hours when B. subtilis was present as a decoy at a 
Figure 4. Treatment of two-strain cultures containing S. epidermidis with violacein and B. bacteriovorus 
HD100. (a) Dual treatment of a mixed culture containing S. epidermidis and A. baumannii using 20 mg/l 
violacein and 1 × 107 PFU/ml B. bacteriovorus HD100. The viabilities were measured after 24 hr (**p < 0.001; 
***p < 0.001) (n = 3). (b) Dual treatment of a mixed culture containing S. epidermidis and K. pneumoniae 
using 20 mg/l violacein and 1 × 107 PFU/ml B. bacteriovorus HD100. The viabilities were measured after 24 hr 
(***p < 0.001) (n = 3).
Figure 5. Dual treatment of polymicrobial culture containing four different pathogens. Impact of 20 mg/l 
violacein alone, 1 × 107 PFU/ml B. bacteriovorus HD100 alone or both antimicrobials together against a culture 
containing four pathogens (S. aureus, B. cereus, A. baumannii and K. pneumoniae, Table 3). The viabilities of the 
culture as a whole were measured after 24 hr. Each of the antimicrobials led to mild but significant losses when 
used alone, but together led to a 99.96% loss in the total pathogen numbers (*p < 0.05; ***p < 0.001) (n = 3).
www.nature.com/scientificreports/
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ratio of approximately 1:2 (decoy:prey). In contrast, the study by Van Essche et al. (2010) found the presence of a 
decoy, i.e., Gram-positive Actinomyces naeslundii ATCC 12104, at a 14-fold excess had no impact on predation of 
Aggregatibacter actinomycetemcomitans ATCC 4371853. Similar results were reported by Loozen et al. (2014) in 
their study with a six-member bacterial community54. The six species present within the community were all oral 
bacteria and included four Gram-negative and two Gram-positive species. Along with the Gram-positive bacte-
rial strains, two of the Gram-negative strains, i.e., Porphyromonas gingivalis and Prevotella intermedia, were not 
predated upon by B. bacteriovorus HD100. However, A. actinomycetemcomitans and Fusobacterium nucleatum are 
both prey and the presence of the four other strains did not hinder their predation.
Clearly some non-prey bacteria can act as decoys and slow down predation initially49, while others have no 
impact53,54. Here, we found the presence of S. aureus did not negatively impact predation. Similar results were 
seen with S. epidermidis. One clear difference between S. aureus and S. epidermidis, though, was the viabilities 
after a dual treatment with K. pneumoniae. With S. epidermidis, the viabilities were comparable with those seen 
after single treatments in Fig. 1. With S. aureus, however, the viabilities of both pathogens were reduced further 
by the dual treatment (Fig. 3).
The activities of violacein and B. bacteriovorus HD100 were also evaluated using a four-member pathogen 
culture, with positive results. As with the two-strain cultures, the presence of the four different strains did not 
significantly deter the activities of either antimicrobial when used alone (Table 3) nor when used together (Fig. 5). 
In the latter case, the number of viable pathogens was reduced by more than 3-log and stands as a clear demon-
stration the potential these two antimicrobials have when used together.
Not only are violacein and B. bacteriovorus HD100 effective against their respective classes of bacteria, they 
are also both active against multidrug resistant pathogens. For violacein, the minimum inhibitory concentrations 
for a wild-type S. aureus and four other strains, including a clinical isolate that is resistant to seven different anti-
biotics, were identical18. Along the same lines, the antibiotic resistant nature of the prey had no obvious impact on 
the ability of B. bacteriovorus to attack28, while predation reduces the presence of the antibiotic resistance marker 
by degrading the prey DNA55. Consequently, violacein and B. bacteriovorus are both active against multidrug 
resistant pathogens. This was illustrated here in experiments with a mixed culture containing multidrug resistant 
strains of S. aureus and A. baumannii. For comparison, we also exposed this culture in parallel to high doses of 
chloramphenicol, gentamicin or both of these antibiotics. With chloramphenicol and/or gentamicin, the culture 
viabilities were not significantly impacted, even though the concentration of each antibiotic was 10-fold higher 
than commonly employed in the lab. In contrast, a dual treatment with violacein and B. bacteriovorus HD100 led 
to a 2- to 3-log loss, a result that is indistinguishable with that in Fig. 3 with the wild-type S. aureus.
Figure 6. Dual treatment of a culture containing multidrug resistant strains of A. baumannii and S. aureus. 
A mixed culture containing A. baumannii alongside S. aureus CCARM 3090 was treated with either 
chloramphenicol, gentamicin, these two antibiotics together (Chl + Gen) or the dual treatment (Predation & 
Violacein). The concentrations of the two antibiotics were 10x higher than commonly used in lab experiments. 
After 24 hr, the cultures were serially diluted and 10 µl spotted onto an agar plate. The image here shows the 
resulting growth, illustrating the much higher degree of killing obtained with the dual treatment protocol.
Initial HEPES (24 hr) Violacein (24 hr) Predation (24 hr)
B. cereus 8.9 ± 1.4 × 106 1.8 ± 0.7 × 107 N.D.a 3.6 ± 1.3 × 107
S. aureus ATCC 25923 2.7 ± 0.4 × 108 3.1 ± 0.2 × 108 N.D. 2.9 ± 0.7 × 108
K. pneumoniae 9.7 ± 0.7 × 107 3.5 ± 0.2 × 108 4.2 ± 0.1 × 108 N.D.
A. baumannii 2.1 ± 0.5 × 108 3.5 ± 0.8 × 108 4.2 ± 0.3 × 108 N.D.
Total (Average) 5.9 × 108 1.03 × 109 8.4 × 108 (81%) 3.2 × 108 (32%)
Table 3. Impact of predation or violacein on the survival of the four pathogens within a mixed population. 
aN.D. – Not detected on the agar plates with a 107 dilution.
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In conclusion, this study evaluated the activities of violacein and B. bacteriovorus HD100 when used together 
against polymicrobial cultures. Violacein, being active primarily against Gram-positive strains such as S. aureus, 
and B. bacteriovorus HD100, which attacks only Gram-negative bacteria, were found to be compatible and not 
diminish the activity of the other. This was demonstrated in cultures containing two and four different bacte-
rial species, including both Gram-positive and Gram-negative strains. When used alone, the overall viabilities 
decreased marginally (less than 1-log reduction) but, when violacein and B. bacteriovorus HD100 were used 
together the number of viable pathogens was reduced by 3-log or greater, even when multidrug resistant patho-
gens were present.
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